Moderna, Inc. (NASDAQ:MRNA) Shares Bought by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. raised its holdings in Moderna, Inc. (NASDAQ:MRNA) by 35.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 30,592 shares of the company’s stock after purchasing an additional 7,939 shares during the period. E Fund Management Co. Ltd.’s holdings in Moderna were worth $1,272,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of MRNA. Knuff & Co LLC raised its holdings in shares of Moderna by 5.4% in the 3rd quarter. Knuff & Co LLC now owns 4,732 shares of the company’s stock valued at $316,000 after buying an additional 244 shares during the period. Stephens Inc. AR raised its holdings in shares of Moderna by 7.9% in the 3rd quarter. Stephens Inc. AR now owns 3,334 shares of the company’s stock valued at $223,000 after buying an additional 245 shares during the period. Allworth Financial LP raised its holdings in shares of Moderna by 17.3% in the 4th quarter. Allworth Financial LP now owns 1,901 shares of the company’s stock valued at $73,000 after buying an additional 281 shares during the period. Howard Capital Management Inc. raised its holdings in shares of Moderna by 3.1% in the 4th quarter. Howard Capital Management Inc. now owns 9,994 shares of the company’s stock valued at $416,000 after buying an additional 297 shares during the period. Finally, Larson Financial Group LLC raised its holdings in shares of Moderna by 53.5% in the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock valued at $61,000 after buying an additional 317 shares during the period. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Stock Down 2.6 %

MRNA opened at $34.30 on Friday. The business has a 50 day moving average price of $36.69 and a two-hundred day moving average price of $49.67. The company has a market cap of $13.23 billion, a PE ratio of -3.70 and a beta of 1.86. Moderna, Inc. has a 52 week low of $29.25 and a 52 week high of $170.47.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on MRNA. Bank of America cut their price target on Moderna from $41.00 to $34.00 and set an “underperform” rating on the stock in a report on Tuesday, February 11th. The Goldman Sachs Group downgraded Moderna from a “buy” rating to a “neutral” rating and cut their price target for the stock from $99.00 to $51.00 in a report on Wednesday, January 29th. Argus downgraded Moderna from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Leerink Partners cut their price target on Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a report on Thursday, January 16th. Finally, Morgan Stanley cut their price target on Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 15th. Four analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $60.63.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.